Eupraxia Pharmaceuticals opened lower at $7.94, compared with its previous close of $8.06. In the last trading session, the stock traded between $7.62 and $8.06. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 3 years ago in Eupraxia Pharmaceuticals is now worth
$ 265.02
Giving a profit of
$ 165.02 (165.02%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 9 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.24 (-3.00%)
Day High
$8.06
Day Low
$7.62
Day Open
$7.94
Prev Close
$8.06
Volume
3,69,522
1W Return
15.50%
1M Return
6.77%
3M Return
16.90%
6M Return
5.36%
1Y Return
19.72%
Fundamentals
Market Cap ($ Mn)
515
PE Ratio
-
PB Ratio
4.30
PEG Ratio
-
ROE
-192.88%
ROCE
-80.35%
EPS (TTM)
$-0.22
Investment Returns
1 Week
15.50%
1 Month
6.77%
3 Months
16.90%
6 Months
5.36%
9 Months
-7.92%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Mar 26
0.0
Jun 26
Updates
11Nov
HC Wainwright raises Eupraxia Pharmaceuticals price target to $16
HC Wainwright & Co. maintains a Buy rating on Eupraxia Pharmaceuticals. Price target raised from $11 to $16. Analyst Brandon Folkes issued the revised recommendation.
Yesterday
11Nov
Eupraxia Pharmaceuticals establishes $125 million ATM equity program
Eupraxia Pharmaceuticals established a $125 million at-the-market (ATM) equity program. Jefferies LLC and Jefferies Securities Inc. act as U.S. and Canadian agents respectively. Company states no immediate plans to utilize the program, citing cash runway until H2 2028.
2 days ago
11Nov
Eupraxia Pharmaceuticals Q3 loss of $0.23 beats estimate
Reported Q3 EPS of $(0.23) per share. Beat analyst consensus estimate of $(0.28) by 17.86%. Losses widened 21.05% from $(0.19) in prior year.
2 days ago
15Oct
Eupraxia Pharmaceuticals hits 120-patient target in RESOLVE trial
Eupraxia Pharmaceuticals reached its enrollment target of 120 patients in the Phase 2b RESOLVE trial for EP-104GI. Over 3,000 injections have been administered with no treatment-related Serious Adverse Events recorded. Interim analysis of the Phase 2b portion is scheduled for December 2026. Statistical reviews confirm that the sample size as designed does not need to be adjusted.
28 days ago
24Sep
Wedbush initiates Eupraxia Pharmaceuticals with Outperform, $17 target
Wedbush analyst Martin Fan initiated coverage on Eupraxia Pharmaceuticals. The firm assigned an Outperform rating to the stock. A price target of $17 was announced for EPRX.
1mo ago
12Aug
Eupraxia Q2 EPS beats estimate despite wider net loss
Eupraxia Pharmaceuticals Inc. reported Q2 2026 EPS of $(0.23), beating analyst estimates of $(0.25) by 8%, despite a widening net loss to $14.5 million driven by increased R&D spending for its lead EoE asset EP-104GI. The company maintains strong liquidity with $133.6 million in cash and investments, supporting operations into the second half of 2028.
